Page last updated: 2024-11-05

zonisamide and Obesity

zonisamide has been researched along with Obesity in 16 studies

Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"In this 10-week, double blind randomized placebo controlled clinical trial, forty one patients with schizophrenia diagnosed according to DSM-IV-TR criteria who were taking a stable dose of atypical antipsychotic are allocated into one of the two groups of zonisamide or placebo group."9.17The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. ( Ghanizadeh, A; Nikseresht, MS; Sahraian, A, 2013)
"Zonisamide at the daily dose of 400 mg moderately enhanced weight loss achieved with diet and lifestyle counseling but had a high incidence of adverse events."9.16Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. ( Allison, DB; Bray, GA; Gadde, KM; Kopping, MF; Wagner, HR; Yonish, GM, 2012)
"Compared with placebo, zonisamide was associated with a significantly greater rate of reduction in binge eating episode frequency (p = ."9.12Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. ( D'Alessio, DA; Guerdjikova, AI; Hudson, JI; Keck, PE; Kotwal, R; Lake, KA; McElroy, SL; Nelson, EB; Welge, JA, 2006)
"Zonisamide and bupropion have been investigated for weight reduction in obese adults."9.12Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. ( Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM, 2007)
"In this short-term, preliminary trial, zonisamide and hypocaloric diet resulted in more weight loss than placebo and hypocaloric diet in the treatment of obesity."9.10Zonisamide for weight loss in obese adults: a randomized controlled trial. ( Franciscy, DM; Gadde, KM; Krishnan, KR; Wagner, HR, 2003)
" We performed an open-label, observational study to assess the effects of zonisamide on weight in overweight female epilepsy patients."7.78Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients. ( Kim, DW; Park, KS; Yoo, MW, 2012)
"In this 10-week, double blind randomized placebo controlled clinical trial, forty one patients with schizophrenia diagnosed according to DSM-IV-TR criteria who were taking a stable dose of atypical antipsychotic are allocated into one of the two groups of zonisamide or placebo group."5.17The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. ( Ghanizadeh, A; Nikseresht, MS; Sahraian, A, 2013)
"Zonisamide at the daily dose of 400 mg moderately enhanced weight loss achieved with diet and lifestyle counseling but had a high incidence of adverse events."5.16Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. ( Allison, DB; Bray, GA; Gadde, KM; Kopping, MF; Wagner, HR; Yonish, GM, 2012)
"Compared with placebo, zonisamide was associated with a significantly greater rate of reduction in binge eating episode frequency (p = ."5.12Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. ( D'Alessio, DA; Guerdjikova, AI; Hudson, JI; Keck, PE; Kotwal, R; Lake, KA; McElroy, SL; Nelson, EB; Welge, JA, 2006)
"Zonisamide and bupropion have been investigated for weight reduction in obese adults."5.12Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. ( Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM, 2007)
"In this short-term, preliminary trial, zonisamide and hypocaloric diet resulted in more weight loss than placebo and hypocaloric diet in the treatment of obesity."5.10Zonisamide for weight loss in obese adults: a randomized controlled trial. ( Franciscy, DM; Gadde, KM; Krishnan, KR; Wagner, HR, 2003)
"On the basis of six randomized controlled trials, zonisamide (ZNS) can be prescribed as add-on treatment in focal adulthood epilepsy in USA and Europe."4.85[Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. ( Janszky, J, 2009)
"The use of topiramate and zonisamide as lead molecules for the design of CA inhibitors targeting isozymes involved in lipogenesis could represent the beginning of a very promising new approach for the treatment of obesity."4.84Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. ( De Simone, G; Di Fiore, A; Supuran, CT, 2008)
" We performed an open-label, observational study to assess the effects of zonisamide on weight in overweight female epilepsy patients."3.78Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients. ( Kim, DW; Park, KS; Yoo, MW, 2012)
"Obesity is ranked as one of the top 10 global health problems and the major concern deriving from it is the exposure of the population to a vast array of chronic pathologies such as cardiovascular and musculoskeletal disorders, type 2 diabetes, cancer, such as colon, breast and endometrial cancer, together with psychological disorders derived from this condition."2.49Antiobesity carbonic anhydrase inhibitors: a literature and patent review. ( Carta, F; Scozzafava, A; Supuran, CT, 2013)
"Obesity is strongly associated with conditions such as hypertension, diabetes mellitus and osteoarthritis that have known adverse health outcomes."2.43Pharmacologic treatment of obesity. ( Cheskin, LJ; Sidhaye, A, 2006)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (50.00)29.6817
2010's8 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ghanizadeh, A1
Nikseresht, MS1
Sahraian, A1
Scozzafava, A1
Supuran, CT2
Carta, F1
Shin, JH1
Gadde, KM5
Østbye, T1
Bray, GA2
Fujioka, K1
Janszky, J2
Horvath, R1
Komoly, S1
Di Fiore, A1
De Simone, G1
Kim, DW1
Yoo, MW1
Park, KS1
Katz, MH1
Kopping, MF1
Wagner, HR3
Yonish, GM2
Allison, DB1
Franciscy, DM1
Krishnan, KR1
Sidhaye, A1
Cheskin, LJ1
McElroy, SL1
Kotwal, R1
Guerdjikova, AI1
Welge, JA1
Nelson, EB1
Lake, KA1
D'Alessio, DA1
Keck, PE1
Hudson, JI1
Foust, MS1
Aylwin, S1
Al-Zaman, Y1
Wallingford, NM1
Sinnayah, P1
Bymaster, FP1
Krishnan, RK1
McKinney, AA1
Landbloom, RP1
Tollefson, GD1
Cowley, MA1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Zonisamide for Weight Reduction in Obese Adults[NCT00275834]225 participants (Actual)Interventional2006-01-31Completed
Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients[NCT00221442]Phase 360 participants (Actual)Interventional2005-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Body Weight

The primary endpoint was weight loss at 1-year, Month-12 weight minus baseline weight, in kilograms. (NCT00275834)
Timeframe: 1 year

Interventionkg (Mean)
Placebo-4.0
Zonisamide 200 mg-4.4
Zonisamide 400 mg-7.3

Inflammatory Markers (CRP)

C reactive Protein (CRP) (NCT00275834)
Timeframe: 1 year

Interventionmg/L (Mean)
Placebo0.523
Zonisamide 200 mg0.536
Zonisamide 400 mg0.443

Proportions of Patients With 10% Weight Loss

This outcomes measure followed the same principles at measurement of proportions of patients with 5% weight loss described elsewhere. (NCT00275834)
Timeframe: 1 year

Interventionparticipants (Number)
Placebo6
Zonisamide 200 mg17
Zonisamide 400 mg24

Proportions of Patients With 5% Weight Loss

These were the proportions of patients losing 5% or more weight at 1-year relative to baseline. The measures were modeled with logistic regressions that included the three-level group proxy and a baseline weight covariate. (NCT00275834)
Timeframe: 1 year

Interventionparticipants (Number)
Placebo23
Zonisamide 200 mg26
Zonisamide 400 mg41

Quality of Life as Measured by HADS_D

Hospital Anxiety and Depression Scale - Depression (HADS-D) The HADS is a 14-item self-administered questionnaire that consists of 2 scales, one measuring anxiety (HADS-A), and the other measuring depression (HADS-D). Each subscale consists of 7 statements and the participant responds as to how each item applies to him/her over the past week on 4-point response scale. Separate scores are calculated for anxiety and depression and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score, the more severe the anxiety or depression. (NCT00275834)
Timeframe: 1 year

Interventionunits on a scale (Least Squares Mean)
Placebo2.12
Zonisamide 200 mg2.76
Zonisamide 400 mg1.95

Waist Circumference

Analyses was based on intent-to-treat ANCOVA. Difference scores from baseline to endpoint (Month-12) for each measure were regressed on the three-level proxy denoting group while controlling for the baseline value of the same measure. Contrasts were subsequently estimated in models, which had a significant overall treatment effect. (NCT00275834)
Timeframe: 1 year

Interventioncm (Mean)
Placebo-4.8
Zonisamide 200 mg-6.1
Zonisamide 400 mg-8.5

Change in Blood Pressure

(NCT00275834)
Timeframe: Baseline, 1 year

,,
Interventionmm Hg (Least Squares Mean)
SystolicDiastolic
Placebo-0.6-1.5
Zonisamide 200 mg-4.4-3.6
Zonisamide 400 mg-1.9-3.9

Change in Lipids

(NCT00275834)
Timeframe: baseline, 1 year

,,
Interventionmg/dL (Least Squares Mean)
Total CholesterolLDL CholesterolHDL CholesterolTriglycerides
Placebo-1.9-2.02.5-11.3
Zonisamide 200 mg4.11.71.50.7
Zonisamide 400 mg-0.1-0.33.4-11.7

Reviews

7 reviews available for zonisamide and Obesity

ArticleYear
Antiobesity carbonic anhydrase inhibitors: a literature and patent review.
    Expert opinion on therapeutic patents, 2013, Volume: 23, Issue:6

    Topics: Animals; Anti-Obesity Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Drug Design; Fruct

2013
Current and emerging medications for overweight or obesity in people with comorbidities.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:11

    Topics: Anti-Obesity Agents; Bupropion; Cinnamates; Comorbidity; Cyclohexanes; Diabetes Mellitus; Dyslipidem

2015
[ZONISAMIDE: FIRST CHOICE AMONG THE FIRST-LINE ANTIEPILEPTIC DRUGS IN FOCAL EPILEPSY].
    Ideggyogyaszati szemle, 2015, May-30, Volume: 68, Issue:5-6

    Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Administratio

2015
Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity.
    Expert opinion on emerging drugs, 2008, Volume: 13, Issue:2

    Topics: Anti-Obesity Agents; Carbonic Anhydrase Inhibitors; Cytosol; Fructose; Humans; Isoxazoles; Mitochond

2008
[Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases].
    Ideggyogyaszati szemle, 2009, Nov-30, Volume: 62, Issue:11-12

    Topics: Anticonvulsants; Bipolar Disorder; Calcium Channels, T-Type; Cholinergic Agents; Dopamine Agents; Dy

2009
Pharmacologic treatment of obesity.
    Advances in psychosomatic medicine, 2006, Volume: 27

    Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Fructose; Humans; Isoxazoles; Lactones; Obe

2006
Emerging concepts in the medical and surgical treatment of obesity.
    Frontiers of hormone research, 2008, Volume: 36

    Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria

2008

Trials

6 trials available for zonisamide and Obesity

ArticleYear
The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial.
    Schizophrenia research, 2013, Volume: 147, Issue:1

    Topics: Adult; Antipsychotic Agents; Body Mass Index; Double-Blind Method; Female; Follow-Up Studies; Humans

2013
Weight changes in obese adults 6-months after discontinuation of double-blind zonisamide or placebo treatment.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:8

    Topics: Adult; Anti-Obesity Agents; Anticonvulsants; Body Mass Index; Cohort Studies; Combined Modality Ther

2014
Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial.
    Archives of internal medicine, 2012, Nov-12, Volume: 172, Issue:20

    Topics: Adolescent; Adult; Aged; Antioxidants; Body Mass Index; Dose-Response Relationship, Drug; Double-Bli

2012
Zonisamide for weight loss in obese adults: a randomized controlled trial.
    JAMA, 2003, Apr-09, Volume: 289, Issue:14

    Topics: Adult; Anti-Obesity Agents; Anticonvulsants; Body Mass Index; Caloric Restriction; Combined Modality

2003
Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:12

    Topics: Adult; Anticonvulsants; Body Mass Index; Bulimia; Dose-Response Relationship, Drug; Double-Blind Met

2006
Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:8

    Topics: Adult; Analysis of Variance; Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Female; Huma

2007

Other Studies

3 other studies available for zonisamide and Obesity

ArticleYear
Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients.
    Epilepsy & behavior : E&B, 2012, Volume: 23, Issue:4

    Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Isoxazoles; L

2012
Zonisamide: no magic bullet.
    Archives of internal medicine, 2012, Nov-12, Volume: 172, Issue:20

    Topics: Female; Humans; Isoxazoles; Male; Obesity; Weight Loss; Zonisamide

2012
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2008, Volume: 33, Issue:12

    Topics: Animals; Anticonvulsants; Appetite Regulation; Benzodiazepines; Biomarkers; Body Weight; Diabetes Me

2008